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Biological medicinePain caused by subcutaneous injections is unpleasant, which may limit patient compliance. The objective
of this study was to use spinal reﬂexes to quantify subcutaneous injection pain. Spinal reﬂexes were mea-
sured using an electromyogram (EMG) test. The effects of injection volume, pH and osmotic pressure
were investigated. The EMG responses increased with injection volume and the acidity of the solution
but did not depend on the osmotic pressure of the solution. The EMG responses differed for subcuta-
neously injected sodium chloride and glucose over the same range of osmotic pressures. Pain caused
by the subcutaneous injections was unrelated to the osmotic ratio up to approximately 5. The injection
pain caused by therapeutic protein solutions was also evaluated. We compared the EMG responses of the
adalimumab and etanercept, as the injection of adalimumab is more painful than that of etanercept in
humans. The EMG magnitude for adalimumab was twice that induced by etanercept as observed for
the EMG tests performed in rats. Therapeutic proteins account for an increasingly large proportion of
pharmaceutical drugs. When a high dose of therapeutic proteins is required, the protein solution must
often be highly concentrated to reduce the injection volume. For patient comfort, it is critical to reduce
injection pain. The EMG test reported here allows subcutaneous injection pain to be quantiﬁed and may
be useful for optimizing drug formulations.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Previous studies have shown that the assessment of the spinal
ﬂexor reﬂex evoked by noxious stimuli in anesthetized rats is a
useful method for assessing nociceptive pain caused by needle
insertion (Okamoto et al., 2012). In this study, we aimed to apply
this method to quantify subcutaneous drug injection pain in
animals. We injected various formulations into rat plantar aspect
subcutaneously and measured the corresponding muscle contrac-
tions using electromyogram (EMG) to assess pain. For example, if
one steps on a pushpin, one withdraws their leg from the pushpin.
When the leg is withdrawn, leg muscles contract, and the degree of
the contraction depends on the intensity of the stimulus. Based on
this phenomenon, we believe that subcutaneous injection pain can
be measured using EMG.
The pain induced due to a subcutaneous injection depends on
several factors, including the pH and the osmolarity of the solution
(Jørgensen et al., 1996) and the buffer (Laursen et al., 2006). Wesought to quantify injection pain and to investigate several factors
that inﬂuence EMG responses.2. Material and methods
2.1. Animals
Male Crl:CD (SD) rats (Charles River Laboratories Japan,
Yokohama, Japan), aged 8 weeks, were used in this study. There
were 8 animals in each study group. The animals were housed 2
per cage under controlled temperature and humidity (23 ± 2 C,
50 ± 10%) and on a 12-h light/dark cycle. The rats had access to
tap water and food ad libitum. This study was approved by the
Committee for Animal Experiments at the Terumo Corporation,
and care and use of the animals conformed to the applicable guide-
lines of the Science Council of Japan.
2.2. Measurement of electromyograms (EMG)
The rats were anesthetized with 3% isoﬂurane (Escain, Pﬁzer
Japan, Tokyo, Japan), and a superﬁcial incision was made in the
skin of the hindlimb. A bipolar stainless steel electrode (TH209-
024, Unique Medical, Tokyo, Japan) was inserted into the
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distance was 1 mm, and a length of the exposed tip was 0.2 mm.
The EMG signals were ampliﬁed with a gain of 20,000 and ﬁltered
(high pass ﬁlter at 100 Hz and low pass ﬁlter at 3000 Hz) using an
extracellular ampliﬁer (ER-1, Cygnus Technology, Delaware Water
Gap, PA, USA) (Chang et al., 2007). The EMG signals were recorded
using PowerLab (input impedance; 1 MX at 100 pF, CMRR;
100 dB at 100 Hz, 16 bit A/D conversion, AD Instruments,
Dunedin, New Zealand) and LabChart (AD Instruments) with a
sampling rate of 10 kHz/s.
A clip-type electrode (TH207-123, Unique Medical) was applied
to the hind paw, and an electrical stimulus (2 ms, 5 mA, 40 Hz) was
delivered using a biphasic stimulus isolator (BSI-950, Dagan,
Minneapolis, MS, USA). The anesthesia level was adjusted until
three consecutive suitable EMG response (amplitude > 100 lV,
duration of response > 10 s) were obtained. The electrical stimuli
were given at 10 min intervals. The anesthesia was adjusted to
1–1.4%.
The area of the full wave rectiﬁed form within the EMG signals
was integrated to yield the magnitude of the EMG response.
2.3. Injection
Test solutions were injected into the rat plantar aspect subcuta-
neously using a syringe pump (MCIP-III, Minato Concept, Tokyo,
Japan). The injection speed was 10 lL/s. For injection, a 1 mL syr-
inge (SS-01T, Terumo, Tokyo, Japan) was used. A 27 gauge blunt
needle (Instech Laboratories, Plymouth Meeting, PA, USA) and a
polyurethane tube (Micro-renathane 025, Braintree Scientiﬁc,
Braintree, MA, USA) were attached to the syringe, and an injection
needle (29G, Terumo) was attached to the other end of the injec-
tion tube. The injection needles were inserted subcutaneously.
Test solutions were injected when an EMG response evoked due
to the needle insertion was observed. The injection needles were
retracted when the EMG responses were terminated. Test solutions
were injected at 10 min intervals, and the injection sites were more
than 2 mm apart. The injection order randomized for each animal.
2.4. Injection solutions
To evaluate the injection volume, saline (Otsuka Normal Saline,
Otsuka, Tokyo, Japan) was injected at a volumes of 20, 50 and
100 lL.
To evaluate pH, PBS (0.01 M, Invitrogen, Carlsbad, CA, USA) was
used as a basic solution. The pH of each stimulus solution was
measured using a pH meter (D-51, Horiba, Kyoto, Japan) and
adjusted with 1 N HCl to pH values of 7, 6, 5, 4 and 3. Each solution
was injected at a volume of 20 lL.
To evaluate the osmotic pressure, a 50% glucose solution
(Otsuka) and a 10% sodium chloride solution (Otsuka) were used.
The glucose solution was diluted with distilled water to 5%, 10%
and 20%. The sodium chloride solution was diluted with distilled
water to 0.9%, 2% and 5%. The pH of each solution was adjusted
to approximately neutral. Twenty microliters of each solution were
injected. The osmotic pressure of the solution was measured usingFig. 1A. The experiman osmometer (Advanced 3D3, Advanced Instruments, Norwood,
MA, USA).
To evaluate the biological medicines, adalimumab (50 mg/mL)
and etanercept (50 mg/mL) were injected twice in each animal.
The drugs were allowed to equilibrate to room temperature for
at least 30 min. The injection volume was 20 lL.
2.5. Statistical analysis
The results are expressed as the mean ± standard error of the
mean (SEM). The data were analyzed using a one-way analysis of
variance followed by Tukey’s post hoc test. For biological medici-
nes, an unpaired t-test was performed. Values of P < 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Experimental procedure and typical EMG response
Fig. 1A shows the experimental procedure.
Fig. 1B shows a representative EMG response. The arrows indi-
cate the time points of needle insertion and solution injection.
3.2. Injection volume
The EMG magnitude increased with increasing injection vol-
umes. The EMG magnitudes for injections of 20, 50 and 100 lL
were 43.3 ± 21.6, 375.2 ± 139.6 and 473.5 ± 117.0 lV  s, respec-
tively. The difference in EMG magnitude between 20 and 100 lL
injections was signiﬁcant (Fig. 2).
3.3. pH
The EMGmagnitudes elicited due to injections of solutions with
pH values of 7, 6, 5, 4 and 3 were 43.4 ± 28.4, 169.1 ± 43.5, 226.6 ±
48.4, 235.5 ± 62.4 and 346.0 ± 98.8 lV  s, respectively (Fig. 3), and
a signiﬁcant difference was observed between pH 7 and pH 3.
3.4. Osmotic pressure
The osmotic pressures for 0.9%, 2%, 5% and 10% sodium chloride
were 292, 633, 1583 and 3282 mOsm/kg H2O, respectively. The
EMG magnitudes elicited due to these solutions were
124.8 ± 87.4, 198.6 ± 143.6, 529.0 ± 93.7 and 851.8 ± 184.1 lV  s,
respectively (Fig. 4A). Signiﬁcant differences were observed
between 0.9% and 10% and between 2% and 10%.
The osmotic pressures for 5%, 10%, 20% and 50% glucose were
292, 610, 1347, and 2917 mOsm/kg H2O, respectively. The EMG
responses were very small for the doses of 5%, 10% and 20%. The
EMG response elicited due to the 50% solution was 345.9 ±
111.6 lV  s (Fig. 4B).
3.5. Biologic medicines
The EMG magnitudes elicited due to administration of adali-
mumab and etanercept were 346.1 ± 87.2 and 147.6 ± 44.9 lV  sental procedure.
Fig. 1B. A typical EMG response due to needle insertion and an injected solution. The arrows represent the time points of needle insertion and solution injection.
Fig. 2. The effects of injection volume on EMGmagnitude. The results are expressed
as the mean ± SEM (n = 8). ⁄P < 0.05 according to Tukey’s test.
Fig. 3. The effects of pH on EMG magnitude. The results are expressed as the
mean ± SEM (n = 8). ⁄P < 0.05 according to Tukey’s test.
Fig. 4. The effects of sodium chloride (A) and glucose (B) solution on EMG
magnitude. The results are expressed as the mean ± SEM (n = 8). ⁄⁄P < 0.01,
⁄⁄⁄P < 0.001 according to Tukey’s test.
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to adalimumab, but the difference was not signiﬁcant (P = 0.0551).4. Discussion
Pain induced by the subcutaneous injection is due to both the
needle insertion and the drug injection. In this EMG test, the
responses caused by the needle insertion and the drug injection
were separated, making it possible to quantify and evaluate each
pain separately.
Solutions were injected at 10 min intervals, and the injection
sites were more than 2 mm apart. No pattern regarding an increaseor decrease in the EMG response was observed depending on the
number of injections. Although the inﬂuence of the previous injec-
tion could not be eliminated, the inﬂuence of the injection order
was minimized by pre-randomizing the injection order for each
animal.
Pain due to subcutaneous injections has been reported to be
related to the injection volume in humans. Jørgensen et al.
(1996) reported that the injection of 1 mL saline caused signiﬁcant
pain. Heise et al. (2014) also reported that injection pain increased
for injection volumes P1200 lL. In the EMG test, the EMG
responses increased with increased injection volumes of saline,
the same tendency which has been previously observed in humans.
The EMG responses were very small for injections of 20 lL and
more than 300 lV  s for injection volumes P50 lL. Thus, for the
evaluation of additional factors, solutions were injected at a
Fig. 5. The effects of biological medicines on EMG magnitude. The results are
expressed as the mean ± SEM (n = 8).
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this injection volume pertaining to rats to the corresponding vol-
ume in humans is not known. A conversion based on body surface
area has been used to extrapolate doses between species. However,
in humans, the perception of injection pain differs depending on
the injection site (Heise et al., 2014), and thus a simple conversion
cannot be performed, representing a limitation of this assay
system.
In this report, we investigated the effect of subcutaneous injec-
tions of non-physiological pH and osmolality solutions on EMG
responses.
It has been reported that human subject begin to feel pain at pH
7.2, and the degree of associated pain increases as the pH of the
stimulus solution is lowered (Ugawa et al., 2002). In the EMG test,
a response was observed at pH 7, which increased with the acidity
of the solution. However, the perception of pain has been reported
to differ among buffers even for solutions at the same pH (Laursen
et al., 2006). Pain intensity may depend not only on the acidity of
the solution but also on the type of buffer.
Subcutaneously injected 5% sodium chloride has been reported
to cause pain in humans due to its hypertonicity (Henderson et al.,
2006). We investigated the effect of osmotic pressure on EMG
responses using subcutaneously injected sodium chloride and glu-
cose. Both sodium chloride and glucose were injected over the
same range of osmotic pressures. The magnitude of the EMG
response increased with increasing concentrations of sodium chlo-
ride. In contrast, the EMG response was small for all except the
highest dose of glucose. In the EMG test, the EMG magnitude eli-
cited due to 5% sodium chloride was more than 500 lV  s. The
osmotic pressure for 5% sodium chloride was 1583 mOsm/kg
H2O, and the osmotic ratio was approximately 5.4, which is com-
parable to a solution of 20% glucose with an osmotic pressure
1347 mOsm/kg H2O and osmotic ratio approximately 4.6. For the
20% glucose solution, the EMG response was quite small. These
results suggest that subcutaneous injection pain is not affected
by osmotic ratios below approximately 5 and that the EMG
responses due to sodium chloride were a feature of the concentra-
tion of sodium chloride itself. The EMG response due to the 50%glucose solution was approximately 300 lV  s. The osmotic pres-
sure for 50% glucose was 2917 mOsm/kg H2O, and the osmotic
ratio was approximately 10. Thus, solutions with osmotic ratios
higher than 10 may cause pain when injected subcutaneously.
Visual analogue scores (VAS) due to subcutaneous injection of
adalimumab and etanercept have been reported as 3.52 and 2.91,
respectively, in humans (Borrás-Blasco et al., 2010, 2013). In the
EMG test, the EMG magnitude for adalimumab was twice as large
as the EMG magnitude for etanercept. The diluent base for adali-
mumab is a phosphate citrate buffer with a pH of 4.9–5.5. The dilu-
ent base for etanercept is a phosphate buffer with a pH range of
6.1–6.5. The difference in the EMG responses may due to the type
of buffer and difference in the pH. The difference in the VAS score
was relatively small compared to the difference in the EMGmagni-
tude. Further evaluation regarding how differences in the EMG
magnitude reﬂect changes in the VAS score are needed.
In summary, subcutaneous injection pain was evaluated using
an EMG test. We used the anesthetized rats so that that pain
sensitivity would be lower than in the conscious state. Several fac-
tors cannot be translated directly to humans, and there are lim-
itations of this study. Nevertheless, this assay system is very
simple, providing a means to quantify subcutaneous injection pain
and will be useful for optimizing drug formulations.
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